Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.

Leger P, Chirwa S, Nwogu JN, Turner M, Richardson DM, Baker P, Leonard M, Erdem H, Olson L, Haas DW.

Pharmacogenet Genomics. 2018 Jan;28(1):1-6. doi: 10.1097/FPC.0000000000000316.

PMID:
29117017
2.

Putting the treatment of paediatric schistosomiasis into context.

Mduluza T, Mutapi F.

Infect Dis Poverty. 2017 Apr 7;6(1):85. doi: 10.1186/s40249-017-0300-8. Review.

3.

UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study.

de Souza MM, Vaisberg VV, Abreu RM, Ferreira AS, daSilvaFerreira C, Nasser PD, Paschoale HS, Carrilho FJ, Ono SK.

Medicine (Baltimore). 2017 Mar;96(11):e6306. doi: 10.1097/MD.0000000000006306.

4.

HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians.

Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E.

Front Pharmacol. 2017 Feb 27;8:90. doi: 10.3389/fphar.2017.00090. eCollection 2017.

5.

Insights into CYP2B6-mediated drug-drug interactions.

Hedrich WD, Hassan HE, Wang H.

Acta Pharm Sin B. 2016 Sep;6(5):413-425. Epub 2016 Aug 9. Review.

6.

Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.

Leger P, Chirwa S, Turner M, Richardson DM, Baker P, Leonard M, Erdem H, Olson L, Haas DW.

Pharmacogenet Genomics. 2016 Oct;26(10):473-80. doi: 10.1097/FPC.0000000000000238.

7.

Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy.

Focà E, Magro P, Motta D, Compostella S, Casari S, Bonito A, Brianese N, Ferraresi A, Rodari P, Pezzoli MC, Quiros-Roldan E, Castelli F.

Int J Mol Sci. 2016 Mar 24;17(4):434. doi: 10.3390/ijms17040434.

8.

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL.

J Antimicrob Chemother. 2016 Jun;71(6):1609-18. doi: 10.1093/jac/dkw005. Epub 2016 Feb 17.

9.

A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.

Likanonsakul S, Suntisuklappon B, Nitiyanontakij R, Prasithsirikul W, Nakayama EE, Shioda T, Sangsajja C.

PLoS One. 2016 Jan 25;11(1):e0147724. doi: 10.1371/journal.pone.0147724. eCollection 2016.

10.

An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.

Swart M, Evans J, Skelton M, Castel S, Wiesner L, Smith PJ, Dandara C.

Front Genet. 2016 Jan 7;6:356. doi: 10.3389/fgene.2015.00356. eCollection 2015.

11.

Privacy-preserving genomic testing in the clinic: a model using HIV treatment.

McLaren PJ, Raisaro JL, Aouri M, Rotger M, Ayday E, Bartha I, Delgado MB, Vallet Y, Günthard HF, Cavassini M, Furrer H, Doco-Lecompte T, Marzolini C, Schmid P, Di Benedetto C, Decosterd LA, Fellay J, Hubaux JP, Telenti A.

Genet Med. 2016 Aug;18(8):814-22. doi: 10.1038/gim.2015.167. Epub 2016 Jan 14.

12.

Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.

Schackman BR, Haas DW, Park SS, Li XC, Freedberg KA.

Pharmacogenomics. 2015 Dec;16(18):2007-18. doi: 10.2217/pgs.15.142. Epub 2015 Nov 26.

13.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Epub 2015 Nov 9. Review.

14.

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.

Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD; INSIGHT Study Group.

EBioMedicine. 2015 May 12;2(7):706-12. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015 Jul.

15.

Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia.

Vardhanabhuti S, Ribaudo HJ, Landovitz RJ, Ofotokun I, Lennox JL, Currier JS, Olson LM, Haas DW.

Open Forum Infect Dis. 2015 Jul 1;2(3):ofv085. doi: 10.1093/ofid/ofv085. eCollection 2015 Sep.

16.

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group.

Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14.

17.

PharmGKB summary: Efavirenz pathway, pharmacokinetics.

McDonagh EM, Lau JL, Alvarellos ML, Altman RB, Klein TE.

Pharmacogenet Genomics. 2015 Jul;25(7):363-76. doi: 10.1097/FPC.0000000000000145. No abstract available.

18.

Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Haas DW, Tarr PE.

Curr Opin HIV AIDS. 2015 Mar;10(2):116-22. doi: 10.1097/COH.0000000000000134. Review.

19.

Pharmacogenomics of antimicrobial agents.

Aung AK, Haas DW, Hulgan T, Phillips EJ.

Pharmacogenomics. 2014;15(15):1903-30. doi: 10.2217/pgs.14.147. Review.

20.

Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting.

Iwuchukwu OF, Feng Q, Wei WQ, Jiang L, Jiang M, Xu H, Denny JC, Wilke RA, Krauss RM, Roden DM, Stein CM.

Pharmacogenomics. 2014 Nov;15(14):1739-1747.

Supplemental Content

Support Center